Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plitidepsin - PharmaMar

Drug Profile

Plitidepsin - PharmaMar

Alternative Names: Aplidin; Aplidine; DDB; Dehydrodidemnin B

Latest Information Update: 28 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmaMar
  • Developer Boryung Pharmaceutical; PharmaMar
  • Class Antineoplastics; Antivirals; Depsipeptides
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Protein synthesis inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma; Multiple myeloma; Peripheral T-cell lymphoma

Highest Development Phases

  • Registered Multiple myeloma
  • Phase II COVID 2019 infections; Non-Hodgkin's lymphoma; T-cell lymphoma
  • No development reported Liposarcoma; Malignant melanoma; Myelofibrosis; Solid tumours
  • Discontinued Leukaemia; Prostate cancer

Most Recent Events

  • 28 Sep 2020 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-myeloma(Combination therapy, First-line therapy) in Czech Republic (IV, Infusion)
  • 28 Sep 2020 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-myeloma(Combination therapy, First-line therapy) in Spain (IV, Infusion)
  • 02 Jul 2020 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by Boryung Pharmaceutical
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top